ArticleCancer research2021
Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 30 citations in OpenAlex.
- Research progress on lysine acetylation (Review).International journal of molecular medicine · 2026Review
- XBP1 signaling from tumor metabolic stress to myeloid driven immunotherapy resistance (Review).International journal of molecular medicine · 2026Review
- Stress-driven reprogramming of plasmacytoid dendritic cells in intrahepatic cholangiocarcinoma defines a reversible targetable immunosuppressive state.World journal of surgical oncology · 2026Article
- Regulatory Mechanisms of XBP1 in Tumorigenesis and Cancer Progression: Challenges and Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Unmasking FCGR2B as a high-grade serous ovarian cancer specific marker of immune suppression and tumor progression through multi-omics mining.Translational oncology · 2026Article
- Targeting the unfolded protein response in cancer: mechanisms, small-molecule inhibitors, and translational challenges.Frontiers in immunology · 2026Review
- Intravenous delivery of mesenchymal stromal cells reverses Müller cell endoplasmic reticulum stress in diabetic retinopathy.Stem cell research & therapy · 2025Article
- The Role of Endoplasmic Reticulum Stress and Unfolded Protein Response in Gynecological Cancers: A Narrative Review.Cureus · 2025Review
- Crosstalk between ferroptosis and endoplasmic reticulum stress: A potential target for ovarian cancer therapy (Review).International journal of molecular medicine · 2025Review
- NCancer gene therapy · 2025Article
- Review
- IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Lactate supports Treg function and immune balance via MGAT1 effects on N-glycosylation in the mitochondria.The Journal of clinical investigation · 2024Article
- ARID1A in Gynecologic Precancers and Cancers.Reproductive sciences (Thousand Oaks, Calif.) · 2024Review
- Emerging mechanisms of the unfolded protein response in therapeutic resistance: from chemotherapy to Immunotherapy.Cell communication and signaling : CCS · 2024Review
- Immunologic Crosstalk of Endoplasmic Reticulum Stress Signaling in Bladder Cancer.Current cancer drug targets · 2024Review
- The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages.Cancer cell international · 2023Article
- Targeting endoplasmic reticulum stress signaling in ovarian cancer therapy.Cancer biology & medicine · 2023Review
- Tumor microenvironmental nutrients, cellular responses, and cancer.Cell chemical biology · 2023Review
- Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.Journal of ovarian research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Joseph A ZundellImmunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-6541-8016
Takeshi FukumotoImmunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania.
Jianhuang LinImmunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-0035-0938
Nail FatkhudinovImmunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania.
Timothy NacarelliImmunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania.
Andrew V KossenkovGene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania.
Qin LiuMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-9964-580X
Joel CasselMolecular Screening and Protein Expression Facility, The Wistar Institute, Philadelphia, Pennsylvania.
Chih-Chi Andrew HuCenter for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, Texas.ORCID 0000-0001-9024-2932
Shuai WuImmunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania. rzhang@wistar.org swu@wistar.org.ORCID 0000-0002-3183-5081
Rugang ZhangImmunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania. rzhang@wistar.org swu@wistar.org.ORCID 0000-0002-7255-2360
The Wistar Institute · USHouston Methodist · US
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Nan Zhang · 1985 to 2026
$75.9MSPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Tian-Li Wang · 2018 to 2026
$20.5MTargeting ER stress response in B-cell chronic lymphocytic leukemiaR01CA163910 · NCI · WISTAR INSTITUTE · PI Chih-Chi Andrew Hu · 2013 to 2026
$4.8MMechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancerR01CA202919 · NCI · WISTAR INSTITUTE · PI Xi Chen, Rugang Zhang · 2016 to 2026
$4.1MTargeting EZH2 in CARM1-expressing epithelial ovarian cancerR01CA163377 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2012 to 2021
$3.7MSynthetic lethality based combination approaches to ARID1A mutation in ovarian cancerR01CA239128 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2019 to 2024
$2.5MPharmacological Blockage of XBP-1s Expression in CancerR01CA190860 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI DEL VALLE, JUAN R, HU, CHIH-CHI ANDREW · 2015 to 2019
$2.3MQuantitative assessment of the role of collagen alterations in ovarian cancerR01CA206561 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CAMPAGNOLA, PAUL J, ELICEIRI, KEVIN WILLIAM · 2016 to 2020
$2.1MMetabolic basis of ARID1A-mutated ovarian cancerR01CA260661 · NCI · WISTAR INSTITUTE · PI Rugang Zhang · 2022 to 2026
$2.0MIntegrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center LevelR50CA211199 · NCI · WISTAR INSTITUTE · PI Andrew V Kossenkov · 2016 to 2026
$1.6MTargeting the ER Stress Response in ARID1A-mutant Ovarian Clear Cell CarcinomaF31CA247336 · NCI · UNIVERSITY OF THE SCIENCES PHILADELPHIA · PI ZUNDELL, JOSEPH · 2020 to 2021
$92kNCI NIH HHS F31 CA247336NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA228991NCI NIH HHS R01 CA163377NCI NIH HHS R01 CA163910NCI NIH HHS R01 CA190860NCI NIH HHS R01 CA202919NCI NIH HHS R01 CA206561NCI NIH HHS R01 CA239128NCI NIH HHS R01 CA260661NCI NIH HHS R50 CA211199
Abstract
The SWI/SNF chromatin-remodeling complex is frequently altered in human cancers. For example, the SWI/SNF component
Indexed as
Endoplasmic Reticulum StressMutationAdenocarcinoma, Clear CellAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell ProliferationDNA-Binding ProteinsEndoribonucleasesFemaleGene Expression Regulation, NeoplasticHistone Deacetylase 6Histone Deacetylase InhibitorsHumansMiceMice, KnockoutARID1A protein, humanArid1a protein, mouseDNA-Binding ProteinsEndoribonucleasesERN1 protein, humanErn1 protein, mouseHistone Deacetylase 6Histone Deacetylase InhibitorsProtein Serine-Threonine KinasesTranscription FactorsX-Box Binding Protein 1XBP1 protein, humanXbp1 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.